The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) was established in 2005. It was formed by a collaborative group of researchers working on genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers.
The aim of CIMBA is to provide sufficient sample sizes to allow large scale studies in order to evaluate reliably the effects of genetic modifiers.
Currently, the Consortium consists of about 70 different study groups, incorporating sites from Europe, North and South America, Australia, Asia and Africa. We have phenotype data for over 46,000 BRCA1 and BRCA2 mutation carriers and DNA samples for about 38,000. These numbers are constantly increasing with the incorporation of new groups.